Clinical Development of Regenerative Medicine Targeted for Intervertebral Disc Disease

Sakai, Daisuke; Schol, Jordy; Watanabe, Masahiko

doi:10.3390/medicina58020267

Cited by 20 publications

(33 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anatomically, the IVD is a large and avascular fibrocartilaginous tissue located between every two neighboring vertebrae. It consists of three main parts: the central nucleus pulpous (NP), surrounding collagenous annulus fibrous (AF), and the two cartilaginous endplates (CEP) that separate AF and NP from the vertebral bodies [ 16 , 17 , 18 , 19 , 20 ]. NP is the hydrophilic core of IVD, composed of collagen II and elastin fibers embedded in an aggrecan-containing gel.…”

Section: Pathogenesis and Etiology Of Intervertebral Disc Degenerationmentioning

confidence: 99%

“…The CEP represents a thin horizontal hyaline cartilage layer through which the IVD connects to each vertebra. Moreover, it forms the main source of nutrient, waste, and gas exchange for the avascular discs [ 18 , 19 ].…”

Section: Pathogenesis and Etiology Of Intervertebral Disc Degenerationmentioning

confidence: 99%

“…Moreover, MSC treatments are considered safe and well-tolerated, potentially limiting the inflammatory environment of the IVD upon transplantation and leading to no severe adverse effects. However, occasional mild-pain-related adverse events might occur [ 2 , 19 ].…”

Section: Strategies For Managing Intervertebral Disc Degenerationmentioning

confidence: 99%

See 2 more Smart Citations

Recent Advances in Managing Spinal Intervertebral Discs Degeneration

Costăchescu

Niculescu

Teleanu

et al. 2022

IJMS

View full text Add to dashboard Cite

Low back pain (LBP) represents a frequent and debilitating condition affecting a large part of the global population and posing a worldwide health and economic burden. The major cause of LBP is intervertebral disc degeneration (IDD), a complex disease that can further aggravate and give rise to severe spine problems. As most of the current treatments for IDD either only alleviate the associated symptoms or expose patients to the risk of intraoperative and postoperative complications, there is a pressing need to develop better therapeutic strategies. In this respect, the present paper first describes the pathogenesis and etiology of IDD to set the framework for what has to be combated to restore the normal state of intervertebral discs (IVDs), then further elaborates on the recent advances in managing IDD. Specifically, there are reviewed bioactive compounds and growth factors that have shown promising potential against underlying factors of IDD, cell-based therapies for IVD regeneration, biomimetic artificial IVDs, and several other emerging IDD therapeutic options (e.g., exosomes, RNA approaches, and artificial intelligence).

show abstract

Section: Pathogenesis and Etiology Of Intervertebral Disc Degenerationmentioning

confidence: 99%

Section: Pathogenesis and Etiology Of Intervertebral Disc Degenerationmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Managing Spinal Intervertebral Discs Degeneration

Costăchescu

Niculescu

Teleanu

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Based on this, cell transplantation is one of the potential biology approaches for IDD. 65 However, the biochemical microenvironment of IVD is rough, with low oxygen concentrations, inadequate nutrition, excessive osmolarity, and high acidity. 35 , 66 Although autologous disc cells are a promising cell source, they have a number of weaknesses in the therapeutic setting: (1) Autologous disc cell extraction, whether by image-guided aspiration or open surgical collection, is an intrusive procedure; (2) collecting disc cells from a healthy IVD may hasten IVD degeneration; (3) disc cells from a degenerated disc may not be functionally perfect for re-implantation.…”

Section: Ascs For Regeneration Of Intervertebral Disc Regenerationmentioning

confidence: 99%

Adipose-Derived Stem Cells (ASCs) for Regeneration of Intervertebral Disc Degeneration: Review Article

Romaniyanto¹,

Mahyudin²,

Prakoeswa³

et al. 2022

SCCAA

View full text Add to dashboard Cite

The intervertebral disc (IVD) is an important structure in the human body because it functions as a weight-bearing. This structure undergoes a process of degeneration like the rest of the body and this process is known as intervertebral disc degeneration (IDD) which is the most common cause of low back pain (LBP). The current common management, either conservative or surgical, is pain-relieving and has not been able to restore degenerated disc optimally. Changes in the IVD microenvironment in IDD conditions make it difficult for the regeneration process to occur. Research to reverse the degeneration process continues to develop, one of them is the use of adipose-derived stem cells (ASCs). ASCs is superior due to the ability to differentiate into several other cells such as adipocytes, chondrocytes, and osteoblasts, it also has ability to act as immunomodulators by stimulating the migration of immune cells to damaged tissues. ASCs becomes a good choice because it is easy to obtain, low donor site morbidity, high proliferation rate, and excellent differentiation abilities. Research on the optimal preparation process for ASCs and their application to various disorders continues to advanced. This study aims to review the potential use of ASCs for regeneration of intervertebral disc degeneration.

show abstract

“…Namely, pro-inflammatory stimuli and/or disc ruptures found in degenerated IVDs are considered to be responsible for the presence of discogenic LBP. Biologically, suppressing these inflammatory responses [ 17 ] and promoting tissue repair within degenerated/degenerating IVDs [ 18 , 19 , 20 ] would be essential treatments for discogenic LBP (see reviews in [ 21 , 22 , 23 ]).…”

Section: Introductionmentioning

confidence: 99%

Platelet-Rich Plasma-Releasate (PRPr) for the Treatment of Discogenic Low Back Pain Patients: Long-Term Follow-Up Survey

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: Clinical studies of platelet-rich plasma (PRP) for the treatment of low back pain (LBP) have been reported; however, less is known about its long-term efficiency. Materials and Methods: This study was a long-term follow-up of a previous prospective clinical feasibility study for the use of PRP releasate (PRPr) to treat discogenic LBP patients. Among 14 patients, 11 patients were evaluated for a long-term survey. The efficacy was assessed by a visual analogue scale (VAS) for LBP intensity and the Roland-Morris Disability Questionnaire (RDQ) for LBP-related disability. Radiographic disc height was evaluated for seven patients. Results: Improvements in VAS and RDQ were sustained at an average of 5.9 years after the intradiscal injection of PRPr (p < 0.01 vs. baseline, respectively). Clinically meaningful improvements (more than 30% decrease from baseline) in VAS and RDQ were identified in 91% of patients at final survey. The radiographic measurement of disc height of PRPr-injected discs showed a mild decrease (13.8% decrease compared to baseline) during the average 5.9 years. Conclusions: The results of this study with a small number of patients suggest that the intradiscal injection of PRPr has a safe and efficacious effect on LBP improvement for more than 5 years after treatment. Further large-scale studies would be needed to confirm the clinical evidence for the use of PRPr for the treatment of patients with discogenic LBP.

show abstract

Clinical Development of Regenerative Medicine Targeted for Intervertebral Disc Disease

Cited by 20 publications

References 95 publications

Recent Advances in Managing Spinal Intervertebral Discs Degeneration

Recent Advances in Managing Spinal Intervertebral Discs Degeneration

Adipose-Derived Stem Cells (ASCs) for Regeneration of Intervertebral Disc Degeneration: Review Article

Platelet-Rich Plasma-Releasate (PRPr) for the Treatment of Discogenic Low Back Pain Patients: Long-Term Follow-Up Survey

Contact Info

Product

Resources

About